Recurrent Ovarian Carcinoma
Showing 26 - 50 of 86
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma Trial in Canada, Singapore, United States
Active, not recruiting
- Ovarian Brenner Tumor
- +11 more
- Adavosertib
- +5 more
-
Duarte, California
- +15 more
Aug 11, 2022
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)
Recruiting
- Bone Sarcoma
- +15 more
- Aldesleukin
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Aug 3, 2022
Recurrent Ovarian Carcinoma Trial in Worldwide (Bevacizumab, Atezolizumab, Chemotherapy)
Active, not recruiting
- Recurrent Ovarian Carcinoma
- Bevacizumab
- +3 more
-
Innsbruck, Austria
- +110 more
Jul 25, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +8 more
- Durvalumab
- Tremelimumab
-
Houston, TexasM D Anderson Cancer Center
Jul 19, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Not yet recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +6 more
- Biopsy
- Pegylated SN-38 Conjugate PLX038
-
Rochester, MinnesotaMayo Clinic
Jul 19, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Active, not recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +11 more
- Aldesleukin
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 13, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +4 more
-
Phoenix, Arizona
- +2 more
Jun 27, 2022
Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston
Recruiting
- Malignant Female Reproductive System Neoplasm
- +24 more
- Quality-of-Life Assessment
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jun 6, 2022
Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Aurora
Active, not recruiting
- Recurrent Endometrial Serous Adenocarcinoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Aurora, ColoradoUniversity of Colorado Hospital
May 24, 2022
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal
Recruiting
- Platinum-Resistant Fallopian Tube Carcinoma
- +6 more
- Lenvatinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
May 17, 2022
Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in
Recruiting
- Malignant Ovarian Epithelial Tumor
- +9 more
- Akt/ERK Inhibitor ONC201
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
May 10, 2022
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma Trial in Salt Lake City, Fairfax (Ribociclib, Belinostat)
Recruiting
- Metastatic Breast Cancer
- Recurrent Ovarian Carcinoma
-
Salt Lake City, Utah
- +1 more
May 3, 2022
Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Shibin Al Kawm (secondary cytoreductive surgery, Chemotherapy)
Withdrawn
- Ovarian Cancer
- Recurrent Ovarian Carcinoma
- secondary cytoreductive surgery
- Chemotherapy
-
Shibīn Al Kawm, Menoufia, EgyptMenoufia University, Faculty of medicine
Apr 9, 2022
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma Trial in
Recruiting
- Advanced Differentiated Thyroid Gland Carcinoma
- +102 more
- Cabozantinib S-malate
- Nivolumab
-
Chicago, Illinois
- +2 more
Apr 5, 2022
Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and
Recruiting
- Ovarian Carcinoma
- +6 more
- Albumin-bound paclitaxel and bevacizumab
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Seattle
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Carboplatin
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Mar 10, 2022
Ovarian Serous Tumor, Recurrent Ovarian Carcinoma Trial in Rochester (Auranofin, Laboratory Biomarker Analysis, Sirolimus)
Active, not recruiting
- Ovarian Serous Tumor
- Recurrent Ovarian Carcinoma
- Auranofin
- +2 more
-
Rochester, MinnesotaMayo Clinic
Mar 22, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Buffalo
Active, not recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Aldesleukin
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Mar 3, 2022
Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in Beijing (6B11-OCIK Injection, Doxorubicin)
Recruiting
- Recurrent Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- 6B11-OCIK Injection
- Doxorubicin
-
Beijing, ChinaPeking University People's hospital
Feb 11, 2022
Recurrent Ovarian Carcinoma Trial in Worldwide (Placebo, Carboplatin, Paclitaxel)
Active, not recruiting
- Recurrent Ovarian Carcinoma
- Placebo
- +6 more
-
Charleroi, Belgium
- +70 more
Feb 7, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +44 more
Jan 10, 2022
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in Los Angeles
Recruiting
- Recurrent Endometrial Carcinoma
- +3 more
- Abemaciclib
- +2 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Oct 28, 2021
Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial in United States (ChemoID Assay, Standard Chemotherapy)
Recruiting
- Recurrent Ovarian Carcinoma
- Platinum-resistant Ovarian Cancer
- ChemoID Assay
- Standard Chemotherapy
-
Phoenix, Arizona
- +9 more
Oct 16, 2021